Aldeyra Therapeutics Inc
Uždarymo kaina
1.53 6.99
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
1.43
Max
1.56
Pajamos | -8.9B -8.9B |
|---|---|
Pelnas, tenkantis vienai akcijai | -0.16 |
Darbuotojai | 7 |
EBITDA | -2.5M -5.5M |
Kitas uždarbis | 2026-11-03 |
|---|
Rinkos kapitalizacija | -1.2M 91M |
|---|---|
Ankstesnė atidarymo kaina | -5.46 |
Ankstesnė uždarymo kaina | 1.53 |
Aldeyra Therapeutics Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Aldeyra Therapeutics Inc Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.